CN117137988A - Traditional Chinese medicine composition and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN117137988A CN117137988A CN202311421885.8A CN202311421885A CN117137988A CN 117137988 A CN117137988 A CN 117137988A CN 202311421885 A CN202311421885 A CN 202311421885A CN 117137988 A CN117137988 A CN 117137988A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- weight
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 241000255789 Bombyx mori Species 0.000 claims abstract description 12
- 244000183278 Nephelium litchi Species 0.000 claims abstract description 12
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 11
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 10
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 10
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 10
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 9
- 241000208368 Euonymus alatus Species 0.000 claims abstract description 9
- 235000015742 Nephelium litchi Nutrition 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 235000005412 red sage Nutrition 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 7
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 240000006766 Cornus mas Species 0.000 claims abstract 4
- 239000000463 material Substances 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 235000021028 berry Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 10
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 239000000284 extract Substances 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 44
- 210000004369 blood Anatomy 0.000 description 44
- 208000024891 symptom Diseases 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- -1 phenanthrenequinone compound Chemical class 0.000 description 7
- 206010036067 polydipsia Diseases 0.000 description 7
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 241000209020 Cornus Species 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- 244000281702 Dioscorea villosa Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000004879 dioscorea Nutrition 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 2
- UPCWCCRFMPIOAP-UHFFFAOYSA-N Hydroxytanshinone Chemical compound C1=CC(C(CCC2O)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 UPCWCCRFMPIOAP-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 2
- DGZBGCMPRYFWFF-ZYOSVBKOSA-N (1s,5s)-6-methyl-4-methylidene-6-(4-methylpent-3-enyl)bicyclo[3.1.1]heptane Chemical compound C1[C@@H]2C(CCC=C(C)C)(C)[C@H]1CCC2=C DGZBGCMPRYFWFF-ZYOSVBKOSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- IXQKXEUSCPEQRD-NRNCYQGDSA-N (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-NRNCYQGDSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- VWEWSCDQMVNOJP-IPOZFMEPSA-N 7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=CC=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)C=C1 VWEWSCDQMVNOJP-IPOZFMEPSA-N 0.000 description 1
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000218202 Coptis Species 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- IHTCCHVMPGDDSL-ZJNDIJRCSA-N Cucurbitacin A Natural products O=C([C@@](O)(C)[C@H]1[C@@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(CO)[C@H]2CC=C2C(C)(C)C(=O)[C@H](O)C[C@@H]12)/C=C/C(OC(=O)C)(C)C IHTCCHVMPGDDSL-ZJNDIJRCSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001369972 Deudorix epijarbas Species 0.000 description 1
- QZJJDOYZVRUEDY-UHFFFAOYSA-N Dihydrocucurbitacin B Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(=O)C1(C)C QZJJDOYZVRUEDY-UHFFFAOYSA-N 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010021000 Hypoglycaemic coma Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000731396 Pueraria montana var. thomsonii Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241001093760 Sapindaceae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229930000766 bergamotene Natural products 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000011046 carnelian Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- JUUBCHWRXWPFFH-UHFFFAOYSA-N hydroxytyrosol Natural products OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229930186179 lupulin Natural products 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- YMBFCQPIMVLNIU-UHFFFAOYSA-N trans-alpha-bergamotene Natural products C1C2C(CCC=C(C)C)(C)C1CC=C2C YMBFCQPIMVLNIU-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition and a preparation method and application thereof, and solves the problems of dependence and side effects of the existing diabetes medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-9 parts of ginseng, 12-14 parts of winged euonymus twig, 11-13 parts of silkworm excrement, 11-13 parts of lychee seed, 11-13 parts of radix trichosanthis, 11-13 parts of Chinese yam, 4-6 parts of coptis chinensis, 4-6 parts of dogwood, 8-9 parts of red sage root, 8-9 parts of radix puerariae and 8-9 parts of schisandra chinensis. Pulverizing Ginseng radix, saviae Miltiorrhizae radix, and rhizoma Dioscoreae into fine powder; decocting the rest rhizoma Dioscoreae, fructus Schisandrae chinensis, ramulus Euonymi, faeces Bombycis, semen litchi, radix Trichosanthis, coptidis rhizoma, corni fructus and radix Puerariae in water twice, filtering, and mixing filtrates; concentrating the filtrate into soft extract, mixing with the fine powder, drying, pulverizing into fine powder, sieving, and mixing; making into pill with water, drying, and making into pill.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a preparation method and application thereof.
Background
Diabetes mellitus is a metabolic endocrinopathy, and is classified into primary and secondary. The former accounts for the majority, has genetic tendency, the basic pathology is metabolic disorder caused by absolute or relative insulin hyposecretion and increased glucagon activity, including sugar, protein, fat, water, electrolyte and the like, and acid-base balance disorder is seriously and frequently caused; it is characterized by diabetes, impaired glucose tolerance and abnormal insulin release tests. Clinically, the patients are asymptomatic in early stage, and symptoms such as polyphagia, polydipsia, diuresis, polydipsia, hunger, emaciation or obesity, fatigue and weakness are not caused until the symptoms, and long-term patients often have lesions such as cardiovascular and cerebrovascular diseases, kidney diseases, eyes and nerves. In recent years, with the rapid development of economy, people's lifestyle and eating patterns have changed greatly, and the eating habits of high sugar and high fat have led to a rapid increase in the number of diabetics.
At present, diabetics mainly control blood sugar by taking/injecting hypoglycemic agents for a long time, and have certain side effects. Many hypoglycemic drugs can stimulate insulin secretion, and under the conditions of irregular diet and unreasonable medication scheme of patients, patients are caused to be hypoglycemic, and severe patients can suffer from hypoglycemic coma. In addition, sulfonylurea drugs have certain side effects on liver and kidney, which cause other diseases of the body. And western medicines have strong dependence, are easy to relapse after stopping taking, and are easy to generate drug resistance after long-term taking. Therefore, there is a need to develop a medicament for treating diabetes which addresses both the symptoms and root causes without damaging other body organs.
Diabetes belongs to the field of diabetes in the traditional Chinese medicine field, and ancient and modern doctors mostly consider that consumptive disease damages yin fluid of liver, spleen and kidney to form the disease, and Zhangjing Yue considers middle-jiao disease to be middle-jiao disease, and the disease is in spleen and stomach. Clinically, there are excessive heat and impairment of yin, and yin deficiency and dryness-heat are causal, while the primary diseases are different in the upper, middle and lower aspects, and the primary diseases are different in the initial aspects, and the secondary diseases are mainly three-in-one diseases, namely late yin impairment and yang, manifesting as yin-yang impairment. In conclusion, in combination with the characteristics of Chinese medicine, development of the traditional Chinese medicine as a main means for improving the symptoms of diabetes is imperative.
Disclosure of Invention
In order to solve the problems of the existing diabetes medicines, the invention provides a traditional Chinese medicine composition, and a preparation method and application thereof.
The technical scheme of the invention is as follows:
a traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
8-9 parts of ginseng, 12-14 parts of winged euonymus twig, 11-13 parts of silkworm excrement, 11-13 parts of lychee seed, 11-13 parts of radix trichosanthis, 11-13 parts of Chinese yam, 4-6 parts of coptis chinensis, 4-6 parts of dogwood, 8-9 parts of red sage root, 8-9 parts of radix puerariae and 8-9 parts of schisandra chinensis.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
8.5 parts of ginseng, 13.5 parts of winged euonymus twig, 12 parts of silkworm excrement, 12 parts of lychee seed, 12 parts of radix trichosanthis, 12 parts of Chinese yam, 5 parts of coptis chinensis, 5 parts of dogwood, 8.5 parts of red sage root, 8.5 parts of radix puerariae and 8.5 parts of shizandra berry.
Preferably, the Chinese medicinal composition is prepared into pills after being extracted.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
s1, weighing ginseng, red sage root and half of Chinese yam, and crushing into fine powder;
s2, decocting the rest half of Chinese yam, shizandra berry, winged euonymus twig, silkworm excrement, lychee seed, radix trichosanthis, coptis chinensis, dogwood and radix puerariae in water twice, filtering and then combining the filtrates;
s3, concentrating the filtrate into thick paste, mixing with the fine powder in the step S1, drying, pulverizing into fine powder, sieving, and uniformly mixing;
s4, making the fine powder obtained in the step S3 into pills, drying, and preparing the pill-shaped traditional Chinese medicine composition.
Preferably, the decocting conditions in step S2 are:
the first water quantity is 6-8 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1-2 hours;
the second water quantity is 5-7 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1-2 hours.
Preferably, the decocting conditions in step S2 are:
the first water amount is 7 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1.5 hours;
the water quantity for the second time is 6 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1.5 hours.
Preferably, the temperature of the drying treatment in step S4 is not higher than 70 ℃.
Preferably, the weight of the pellet-shaped traditional Chinese medicine composition obtained in the step S4 is 25% -35% of the total weight of the raw materials.
Preferably, the weight of the pellet-shaped Chinese medicinal composition obtained in the step S4 is 29% of the total weight of the raw materials.
The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating diabetes.
The raw materials in the invention are recorded in pharmacopoeia. Wherein the radix Salviae Miltiorrhizae is dried rhizome of Salvia miltiorrhzab ge of Labiatae, and contains crystalline phenanthrenequinone compound: tanshinone I, tanshinone IIA, tanshinone IIB, cryptotanshinone, hydroxy tanshinone, methyl tanshinone, dihydroxytanshinone I, etc. and isomers thereof. Pharmacological action: the radix salviae miltiorrhizae has the effects of removing blood stasis, relieving pain, activating blood, dredging channels, clearing heart fire and relieving restlessness. The modern researches mainly show that tanshinone has the effects of resisting arteriosclerosis, reducing myocardial infarction area, resisting coagulation and thrombosis, improving microcirculation, protecting liver, regulating tissue repair and regeneration, resisting inflammation and resisting tumor, etc.
The coptis root source is dried rhizome of Coptis chinensis Franch, coptis deltoidea C.Y. Cheng et Hsiao or Coptiseteteta wall of Ranunculaceae, contains berberine, coptisine, methylcoptisine, palmatine, jakogazine, phellodendrine, etc., contains ferulic acid, 3, 4-dihydroxyphenethyl alcohol glucoside, 3-carboxyl-4-hydroxyphenoxyglucoside, 2,3, 4-trihydroxybenzoic acid, etc., and the berberine hydrochloride is hydrophilic quaternary ammonium salt. Pharmacological action: has effects in resisting pathogenic microorganism, relieving inflammation, inhibiting central nervous system, improving cardiovascular function, relieving cerebral ischemia, and reducing blood lipid. Has the functions of treating nongonococcal urethritis, bacillary dysentery, diabetes, etc. clinically.
The ginseng base source is dried root and rhizome of Panax ginseng C.A. Mey of Araliaceae, and the whole plant of Panax ginseng contains chemical components such as saponin and volatile oil. Pharmacological action: has effects in promoting learning and memory, cardiovascular system and blood system, pituitary-adrenocortical system, nucleic acid and protein synthesis, blood sugar, tumor, cell activity, immunity, oxidation and aging.
The Schisandra chinensis source is dry mature fruit of Schisandra chinensis (Turcz.) of Magnoliaceae, and the total lignin content in Schisandra chinensis fruit is 18.1-19.2%. Pharmacological action: has effects in preventing liver injury, protecting against oxygen free radical injury, improving liver detoxification function, resisting aging, tranquilizing mind, improving immunity, relieving ulcer, relieving inflammation, resisting stress, preventing caries, and protecting genital system.
The powder Ge Jiyuan is dry root of Pueraria thomsonii Pueraria thomsoni benth of Leguminosae, contains multiple flavonoid components, mainly daidzein and puerarin. In addition, there are daidzein 4, 7-diglucoside, 7-xyloside puerarin and 4, 6-diacetyl puerarin. Pharmacological action: regulate cardiac function.
The Euonymus alatus (Thunb.) Sieb of Celastraceae contains cardiac glycoside and alkaloid, and also contains 4-stigmastane-3-one, 4-stigmastane-3, 6-dione, etc. Pharmacological action: has effects in reducing blood sugar, increasing myocardial nutritional blood flow, improving oxygen and nutrient supply, inhibiting thrombosis, and relieving arrhythmia.
The silkworm excrement source is dry excrement of silkworm of Bombyx mori Linnaeus of Bombycis, and contains chlorophyll, carotene, beta-sitosterol, cholesterol, ergosterol, tetracosanol, lupulin, and other components, and also contains various free amino acids. Pharmacological action: has inhibiting effect on in vitro liver cancer tissue culture cells.
The radix Trichosanthis is derived from dried root of Trichosanthes kirilowii Maxin or Trichosanthes kirilowii Harlls of Cucurbitaceae, and contains trichosanthin, trichosanthis radix polysaccharide A, B, C, D, E, polysaccharide, bryophyte alkyd, cucurbitacin B, D, etc. Pharmacological action: has abortion inducing, early pregnancy resisting, anticancer, antibacterial, and blood sugar increasing effects.
The cornel source is dried mature pulp of cornel Cornas officinalis Sieb et Zucc of cornelian family, contains tannins and glycosides, and also contains volatile oil and various amino acids. Pharmacological action: has antiinflammatory, antishock, heart strengthening, blood sugar lowering, and immunity enhancing effects.
The litchi seed source is dried mature seed of Lichi chinensis Sonn of Sapindaceae, contains saponin 1.12%, tannin 3.43%, and trace volatile oil contains 3-hydroxy butanone, and bergamotene. Pharmacological action: has the functions of reducing blood sugar and enhancing the oxidization resistance and blood lipid regulation of diabetic rats, and the litchi seeds have toxicity but very low toxicity.
The yam-based source is dried rhizome of Dioscorea opposita Dioscorea opposita thunder. Of Dioscoreaceae, contains diosgenin, dopamine, rhizoma Dioscoreae, allantoin, glycoprotein and polysaccharide. Pharmacological action: has antioxidant and blood sugar reducing effects, and also has certain effects on digestive system and immunity.
Compared with the prior art, the invention has the following specific beneficial effects:
1. from the theory of traditional Chinese medicine, the ginseng taste in the recipe is sweet and warm and supplements deficiency, can tonify qi of lung, spleen and kidney, and can promote the production of body fluid to quench thirst; ramulus Euonymi is bitter in taste and good at strengthening yin, has the effect of cold entering blood, is good at resolving dryness-heat of yin, quenching thirst and clearing fire, and activating blood and dissolving stasis, and the two medicines are combined together to be used as monarch medicines;
qi is the general and blood is the mother of Qi, qi deficiency promotes weakness, blood circulation is unsmooth and is slowly astringed, so that blood stasis is caused, namely 'Qi deficiency is remained'; yin deficiency with excessive fire, decoction of body fluids, homology of body fluids and blood, and lack of body fluids can cause viscous and unsmooth blood, which is called "yin deficiency with blood stagnation"; silkworm excrement and lychee seeds are compatible, and the effects of activating blood and promoting qi circulation are achieved, so that the effect of restoring qi and blood is achieved; radix Trichosanthis is sweet, slightly bitter and slightly cold, and is good at clearing lung and stomach excessive heat, promoting fluid production and quenching thirst; the yam not only can invigorate qi of spleen, lung and kidney, but also can invigorate yin of spleen, lung and kidney; the four materials are taken as ministerial drugs;
coptis chinensis has the effects of clearing stomach fire, and relieving symptoms of hunger, polydipsia and polydipsia; fructus Corni has effects of nourishing liver and kidney, replenishing essence and nourishing yin; the red sage root has the functions of promoting blood circulation to remove blood stasis and promoting tissue regeneration; powder Ge Ganliang, while clearing heat, can promote the ascending of qi of the spleen and stomach to promote the production of body fluid and quench thirst; the four materials are taken as adjuvant drugs;
fructus Schisandrae chinensis is sweet in nature, has effects of invigorating qi, promoting production of body fluid, astringing lung qi, and nourishing kidney yin, and is used as a guiding drug;
the above medicines are combined to make qi and yin both be supplemented and blood stasis be smooth, so that various symptoms of diabetes can be relieved.
2. The prescription of the invention has reasonable design and strict compatibility, and has definite curative effect through long-term clinical verification.
3. The invention is composed of Chinese medicinal materials, has low cost, no toxic or side effect, and can not cause damage to other organs of the body after long-term administration.
Detailed Description
The following examples are provided to better understand the technical aspects of the present invention and should not be construed as limiting the present invention.
Examples
S1, weighing 278g of ginseng, 278g of red sage root and 195g of yam, and crushing into fine powder;
s2, weighing 195g of Chinese yam, 278g of shizandra berry, 444g of winged euonymus twig, 390g of silkworm excrement, 390g of lychee seed, 390g of radix trichosanthis, 167g of rhizoma coptidis, 167g of dogwood and 278g of radix puerariae, adding 7 times of water, decocting for 1.5 hours, filtering, adding 6 times of water, decocting again for 1.5 hours, filtering, and combining the filtrates;
s3, concentrating the filtrate under reduced pressure to obtain thick paste, uniformly mixing the thick paste with the fine powder in the step S1, drying, crushing into fine powder, sieving and uniformly mixing;
s4, making the fine powder obtained in the step S3 into pills, and then drying at 70 ℃ to finally obtain 1000g of the pill-shaped traditional Chinese medicine composition.
Effect example.
50 diabetics are selected, and the ages are 30-60, wherein 25 diabetics are men and 25 women. The 50 diabetics were dosed with the clinical test samples prepared in the above examples three times a day, one granule at a time, eight weeks as a course of treatment.
The treatment effect judgment criteria are as follows:
the effect is shown: the symptoms basically disappear after treatment, the fasting blood sugar is less than 7.2mmol/L, the postprandial blood sugar is less than 8.3mmol/L, the total amount of 24h urine sugar is less than 10.0g, or the total amount of blood sugar and 24h urine sugar is reduced by more than 30 percent compared with the total amount before treatment.
The method is effective: the symptoms are obviously improved after treatment, the fasting blood sugar is less than 8.3mmol/L, the postprandial blood sugar is less than 10.0mmol/L, the total amount of 24h urine sugar is less than 25.0g, or the total amount of blood sugar and 24h urine sugar is reduced by more than 10 percent compared with the total amount before treatment.
Invalidation: the symptoms are not obviously improved after the treatment, and the blood sugar and urine sugar drop does not reach the above standard.
Treatment results: after one treatment course of administration treatment, the blood sugar is detected, 41 patients are effective, 7 patients are effective, 2 patients are ineffective, and the total effective rate is 96 percent.
In conclusion, the medicine provided by the invention accords with the dialectical theory of traditional Chinese medicine in terms of medicinal material selection and compatibility, and has a good effect of treating diabetes.
Typical cases:
1. mr. Prune, 48 years old, had diabetes for nearly one year. By detecting fasting blood glucose 8.6mmol/L, postprandial 2h blood glucose 11.9mmol/L, urine protein++, symptom: dry mouth and tongue, irritability, emaciation, yellow urine and yellow tongue coating. The diagnosis is yin deficiency and internal heat, kidney essence deficiency and diabetes.
After taking the medicine of the embodiment for one treatment period, the dry mouth of the Mr. prune is improved, and the urine color is basically recovered to be normal. The fasting blood glucose of the Mr. prune is detected to be reduced to 6.7mmol/L, the postprandial blood glucose of 2h is 7.5mmol/L, the medicine is stopped after two treatment courses of continuous administration, the fasting blood glucose of the Mr. prune is detected to be 5.5mmol/L, and all other indexes are normal. And returning after one year, wherein all test indexes are normal.
2. The patient is white for women, 36 years old, and symptoms such as thirst, polydipsia, emaciation, dysphoria, poor sleep, slow response and the like appear in the last half year. The fasting blood glucose is detected to be 9.4mmol/L, and the postprandial blood glucose is detected to be 12.8mmol/L for 2h. The primary diagnosis is diabetes.
After taking the medicine described in this example for one treatment period, the symptoms of polydipsia in white women disappeared, the sleep was improved, the emotion was improved, the weight was increased, the fasting blood glucose level was reduced to 7.0mmol/L, and the postprandial blood glucose level was 8.2mmol/L for 2h. And (3) continuing taking for two courses of treatment, and detecting that the fasting blood glucose value is stabilized between 5.8 mmol/L and 6.5mmol/L during the taking period of the white ladies, wherein all other indexes are normal. And returning after stopping taking medicine for one year, and ensuring that all test indexes are normal.
3. The patient is born by the first person, 59 years old, and is diabetic due to polydipsia, polyphagia, diuresis, dizziness, debilitation and the like, and the fasting blood sugar is 13.8mmol/L through detection, which is diagnosed by deficiency of liver-yin and kidney-yin and impairment of both qi and yin.
After taking the medicine of the embodiment for one treatment period, the symptoms are relieved by detecting the fasting blood glucose by 9.4mmol/L, and after continuing to take the medicine for two treatment periods, the medicine for detecting the fasting blood glucose by 7.0mmol/L is effective in treatment, and is consolidated after continuing to take the medicine for two treatment periods. And returning after stopping taking medicine for one year, and ensuring that all test indexes are normal.
It should be noted that the foregoing is only preferred embodiments of the present invention, and these embodiments are based on different implementations of the overall concept of the present invention, and the scope of the present invention is not limited thereto, and any changes or substitutions easily conceivable by those skilled in the art within the technical scope of the present invention should be covered in the scope of the present invention. Therefore, the protection scope of the present invention should be subject to the protection scope of the claims.
Claims (10)
1. The traditional Chinese medicine composition is characterized by being prepared from the following raw materials in parts by weight:
8-9 parts of ginseng, 12-14 parts of winged euonymus twig, 11-13 parts of silkworm excrement, 11-13 parts of lychee seed, 11-13 parts of radix trichosanthis, 11-13 parts of Chinese yam, 4-6 parts of coptis chinensis, 4-6 parts of dogwood, 8-9 parts of red sage root, 8-9 parts of radix puerariae and 8-9 parts of schisandra chinensis.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
8.5 parts of ginseng, 13.5 parts of winged euonymus twig, 12 parts of silkworm excrement, 12 parts of lychee seed, 12 parts of radix trichosanthis, 12 parts of Chinese yam, 5 parts of coptis chinensis, 5 parts of dogwood, 8.5 parts of red sage root, 8.5 parts of radix puerariae and 8.5 parts of shizandra berry.
3. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared into pills after being extracted.
4. A method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 3, comprising the steps of:
s1, weighing ginseng, red sage root and half of Chinese yam, and crushing into fine powder;
s2, decocting the rest half of Chinese yam, shizandra berry, winged euonymus twig, silkworm excrement, lychee seed, radix trichosanthis, coptis chinensis, dogwood and radix puerariae in water twice, filtering and then combining the filtrates;
s3, concentrating the filtrate into thick paste, mixing with the fine powder in the step S1, drying, pulverizing into fine powder, sieving, and uniformly mixing;
s4, making the fine powder obtained in the step S3 into pills, drying, and preparing the pill-shaped traditional Chinese medicine composition.
5. The method of preparing a Chinese medicinal composition according to claim 4, wherein the decocting conditions in step S2 are:
the first water quantity is 6-8 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1-2 hours;
the second water quantity is 5-7 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1-2 hours.
6. The method of preparing a Chinese medicinal composition according to claim 4, wherein the decocting conditions in step S2 are:
the first water amount is 7 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1.5 hours;
the water quantity for the second time is 6 times of the weight of the medicinal materials, and the medicinal materials are decocted for 1.5 hours.
7. The method of preparing a pharmaceutical composition according to claim 4, wherein the drying process in step S4 is performed at a temperature of not higher than 70 ℃.
8. The method for preparing a pharmaceutical composition according to claim 4, wherein the weight of the pellet-shaped pharmaceutical composition obtained in step S4 is 25% -35% of the total weight of the raw materials.
9. The method of preparing a pharmaceutical composition according to claim 4, wherein the weight of the pellet-shaped pharmaceutical composition obtained in step S4 is 29% of the total weight of the raw materials.
10. Use of a Chinese medicinal composition according to any one of claims 1-3 in the manufacture of a medicament for the treatment of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311421885.8A CN117137988A (en) | 2023-10-31 | 2023-10-31 | Traditional Chinese medicine composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311421885.8A CN117137988A (en) | 2023-10-31 | 2023-10-31 | Traditional Chinese medicine composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117137988A true CN117137988A (en) | 2023-12-01 |
Family
ID=88912409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311421885.8A Pending CN117137988A (en) | 2023-10-31 | 2023-10-31 | Traditional Chinese medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117137988A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1248470A (en) * | 1999-09-03 | 2000-03-29 | 山西巨龙糖尿病研究所 | Chinese patent drug-Yibao for treating diabetes |
| CN1292272A (en) * | 2000-08-31 | 2001-04-25 | 史启茂 | Medicine for curing diabetes and its preparation method |
| CN101352512A (en) * | 2007-07-27 | 2009-01-28 | 北京亚东生物制药有限公司 | Chinese medicine composition for treating diabetes and method for preparing the same |
| CN101579471A (en) * | 2009-06-29 | 2009-11-18 | 毛顺卿 | Medicine for curing diabetes |
| CN103083531A (en) * | 2011-10-27 | 2013-05-08 | 彭竹妍 | Drug for treating diabetes |
-
2023
- 2023-10-31 CN CN202311421885.8A patent/CN117137988A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1248470A (en) * | 1999-09-03 | 2000-03-29 | 山西巨龙糖尿病研究所 | Chinese patent drug-Yibao for treating diabetes |
| CN1292272A (en) * | 2000-08-31 | 2001-04-25 | 史启茂 | Medicine for curing diabetes and its preparation method |
| CN101352512A (en) * | 2007-07-27 | 2009-01-28 | 北京亚东生物制药有限公司 | Chinese medicine composition for treating diabetes and method for preparing the same |
| CN101579471A (en) * | 2009-06-29 | 2009-11-18 | 毛顺卿 | Medicine for curing diabetes |
| CN103083531A (en) * | 2011-10-27 | 2013-05-08 | 彭竹妍 | Drug for treating diabetes |
Non-Patent Citations (2)
| Title |
|---|
| 母春丽: "芪参消渴胶囊治疗2型糖尿病125例临床研究", 内蒙古中医药, pages 3 - 4 * |
| 钟磊英 等: "浅论治疗"消渴病"的纯中药院内制剂"五黄降糖片"的组方", 世界最新医学信息文摘, vol. 1, pages 30 - 31 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071048B (en) | Traditional Chinese medicine composition for treating alzheimer diseases and preparation method of traditional Chinese medicine composition | |
| CN102188613B (en) | Traditional Chinese medicine preparation for treating diabetes | |
| CN102343023A (en) | Medicinal composition and preparation method and application thereof | |
| Zhang et al. | Ancient records and modern research on the mechanisms of Chinese herbal medicines in the treatment of diabetes mellitus | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN111729064A (en) | Traditional Chinese medicine composition for invigorating spleen and activating yang and application thereof | |
| CN104491342A (en) | Medicament for treating diabetes and preparation method thereof | |
| CN103446503A (en) | Traditional Chinese medicine composition for treating type II diabetes mellitus | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN101513474A (en) | Chinese medicinal oral liquid for treating diabetes | |
| CN112717113B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and paste formula and application thereof | |
| CN117137988A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
| CN112970992A (en) | Solid beverage suitable for diabetes patients and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN112156162B (en) | Medicine for protecting gastric mucosa and preparation method thereof | |
| CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
| CN104547259B (en) | A kind of Traditional Chinese medicine for decreasing blood sugar acetum | |
| CN109430721A (en) | A kind of wheat embryo composition and preparation method thereof with hypoglycemic effect | |
| CN103585495A (en) | Capsule for treating diabetic kidney damage | |
| CN103860877A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
| US20230405071A1 (en) | Compositions and methods useful for management of blood sugar | |
| KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
| CN106376928A (en) | Method for preparing compound dendrobium officinale health product assisting in reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |